Merrimack Pharmaceuticals

Latest Headlines

Latest Headlines

Sanofi, Merrimack rack up third straight failure for lead cancer drug

Merrimack Pharmaceuticals and its partners at Sanofi are back with another trial failure to report on the biotech's lead drug, MM-121. Combined with exemestane, the drug failed to improve progression-free survival among a group of ER/PR+, HER2 negative breast cancer patients. 

Sanofi, Merrimack cancer drug flops (again) in second round of PhII program

Seven months after a mid-stage cancer drug from Sanofi and Merrimack Pharmaceuticals flunked its first mid-stage test, researchers are back with another failure to report. The Cambridge, MA-based biotech said that MM-121 (SAR256212), partnered with Sanofi in a $530 million deal, failed to hit the primary endpoint on progression free survival for ovarian cancer when combined with Taxol. Once again, though, the investigators are pointing to a subpopulation which benefited from the drug.

Merrimack's lead cancer drug flunks first of three PhII tests

Merrimack Pharmaceuticals has nailed down the top-line results for one group of cancer patients in a mid-stage trial of Tarceva combined with its lead drug MM-121, partnered with Sanofi. And it's not good.

Top 10 biotech IPOs of 2012

After taking a beating in previous years, biotech has been hot sector on Wall Street this year. The Nasdaq Biotech Index has shot up 30% this year compared with 15% growth in the broader market. And the fact that this year's total number of biotech IPOs already matches that of 2011 indicates that there could be a growing appetite for these types of investments. But there's no indication that we're on the verge of, or will ever, return to the go-go years of the 1990s when biotechs more easily went public at lofty values. Here's the full report >>

Supernus IPO spotlights perils, potential of going public

Supernus Pharmaceuticals came out of the IPO gate this morning, pricing its shares at a hefty discount in order to complete its long-planned effort to go public.

Merrimack Pharma stumbles out of the IPO gate

Merrimack's shares fell 13.7% from the opening price of $7 per share, giving the developer of cancer drugs a lackluster public debut.

Merrimack Pharma discounts expectations in $100M IPO

Merrimack Pharmaceuticals, a Cambridge, MA-based developer with 5 cancer therapies in the pipeline, is hoping that it can finally pull off an IPO.

Osteoporosis drug developer Radius Health braves chilly IPO market

After burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million. Radius is betting that it can

Merrimack Pharma scraps IPO

Merrimack Pharmaceuticals ' attempt to buck the trend on IPOs ended in failure today. The developer, a 2011 Fierce 15 company, has 5 drugs in the clinic and reportedly scrapped its offering saying

Fledgling Verastem outlines investor strategy behind high-risk $50M IPO

As today's report on 2011's small class of biotech IPOs makes clear, this is a lousy time for a drug developer to go public--even if it has a compelling late-stage program to boast about. But